Advertisement
|
|
|
|
|
Free Trial
Description: Stephen Turner is SCOLR Pharma CEO/President/CTO. With a Lead411 subscription, SCOLR Pharma email addresses ( @scolr.com ) of the executives are viewable. Other information includes Stephen Turner email, phone, and extension.
Be sure to check our Linkedin tab on the company page. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Turner can be found at Executive Directory - Turner.
|
Add Stephen Turner Information
Site Reference: http://www.scolr.com/news/?m=200702
Stephen Turner SCOLR Pharma’s Vice President and Chief Technology Officer, said, “The data from this second ondansetron study provides additional evidence that our CDT formulation technology is capable of producing a ‘once daily’ sustained release tablet. We intend to provide additional information on our trial results later this year at future investor conferences and at the Annual Controlled Release Society Meeting in Long Beach, California.” Turner further noted, “The unique nature of this compound will require further investigation, but the data from this most recent study provides the basis for us to proceed with final product optimization and subsequent confirmation studies.” Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline’s drug to prevent chemotherapy and radiation related nausea and vomiting. In 2005, GlaxoSmithKline reported over $1.5 billion in global Zofran® sales. In the past several months, several generic 8 milligram (mg) immediate release ondansetron products have been approved by the FDA.
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
